1800 – IncobotulinumtoxinA (XEOMIN) injection code for chronic sialorrhea treatment

New Medicare Benefits Schedule items for codependent application (MSAC and Pharmaceutical Benefits Advisory Committee).

Injection of incobotulinumtoxinA into salivary glands to decrease saliva production to control chronic sialorrhea. 

Sialorrhea, also known as hypersalivation or excessive drooling, is a condition characterised by spillage of saliva from the lips. It is considered abnormal after the age of 4. Chronic sialorrhea, where salival control cannot be maintained either through excessive salival production or saliva pooling, can be the result of hypersecretion, anatomic abnormalities, or neurological conditions. 

This submission focuses on chronic sialorrhea as a result of neurological conditions or disorders such as Parkinson's disease, cerebral palsy, stroke, etc. Chronic sialorrhea can result in a significant reduction in quality of life for the patient and/or their families and carers, as well as a risk of dehydration, choking, aspiration, and pneumonia.

The following consultation deadlines apply:

• Pre-PASC consultation deadline: Not applicable
• Pre-MSAC consultation deadline: Not applicable

This application will be considered at the following meetings:

• PASC meeting: Bypassing PASC
• ESC meeting: Bypassing ESC
• MSAC meeting: 3-4 April 2025

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.